---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-001586"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2025-01-07T23:59:59+00:00"
generated_at: "2026-05-28T08:46:32.333195+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acurx Pharmaceuticals prices $2.5M registered direct offering of 2.46M shares at $1.015

## Summary
- Gross proceeds ~$2.5M from 2,463,058 shares at $1.015/share in registered direct offering.
- Concurrent private placement of Series E warrants to buy up to 2,463,058 shares at $0.90, exercisable for 5 years.
- Net proceeds to be used for working capital and general corporate purposes; closing expected Jan 7, 2025.
- Placement agent H.C. Wainwright receives 7% cash fee and warrants for 147,783 shares at $1.2688.
- Affiliate investors (including CEO and Executive Chairman) purchase 167,488 shares in the offering.

## SEC filing metadata
- accession: 0001104659-25-001586
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2025-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465925001586/0001104659-25-001586-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465925001586/tm252142d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-001586
- JSON: https://secwatch.observer/filing/0001104659-25-001586.json
- Plain text: https://secwatch.observer/filing/0001104659-25-001586.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.